Astute Analytica publishes a research report on the Asia Pacific Preventive Vaccines Market. The analysis report contains in-depth data about demand, growth, opportunities, challenges, and restraints. In addition, it provides a thorough examination of the structure and possibility of global and regional industries.
Asia Pacific Preventive Vaccines Market was valued at US$ 19.8 billion in 2022 and is projected to surpass the market valuation of US$ 55.8 billion by 2031 at a CAGR of 7.22% during the forecast period 2023–2031.
It analyses the market’s regional trends, size, expansion prospects, and important factors in each region. Additionally, it acknowledges the impact of COVID-19, including updates on the Omicron mutation study, on the market. Both the direct and indirect effects of the pandemic on related industries are taken into account and discussed in the report.
The report gives a thorough analysis of the Asia Pacific Preventive Vaccines Market, covering regional trends, market size, prospects for expansion, and important market factors in each region. In 2021, the United States Gross Domestic Product (GDP) value was US$ 23,315.08 billion, according to verified data from the World Bank. In terms of GDP, the United States accounts for 10.41% of the global economy. The mixed economy of the United States is very advanced. By nominal GDP, it has the largest economy in the world, and by purchasing power parity (PPP), it is second only to China in size.
The leading companies mentioned are
- Bharat Biotech
- CanSino Biologics
- Emergent BioSolutions Inc.
- GlaxoSmithKline PLC
- Novavax Inc.
- BioNTech
- Daiichi Sankyo Co. Ltd
- Inovio Pharmaceuticals, Inc.
- Moderna
- Johnson & Johnson
- Merck & Co.
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd
- Sinovac
- Other prominent players
The report also acknowledges the impact of COVID-19, including updates on the Omicron mutation study, on the market. It considers both the direct impact of the pandemic and the indirect influence on related industries. The observations on the pandemic’s impact are included in the report.
Furthermore, the report divides geographical regions into several major categories for production, consumption, revenue (in US dollars), and market share analysis. It discusses the predicted growth of the market in these regions between 2021 and 2031.
The segmentation overview of the Asia Pacific Preventive Vaccines Market includes
By Type
- Conjugate Vaccines
- Inactivated Vaccines
- Subunit and Polysaccharide Vaccines
- Live Attenuated Vaccines
- Messenger RNA (mRNA) Vaccines
- Nucleic Acid Vaccines
- Viral Vector Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Others
By Disease Indication
- Bacterial Diseases
- Viral Diseases
By Route of Administration
- Intramuscular
- Subcutaneous
- Oral Administration
- Intra Venous
- Others
By Patient Group
- Adult
- Pediatric
By End User
- Hospitals
- Clinics
- Vaccination Centers
- Academic & Research Institutes
By Region
- China
- India
- Japan
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific